Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...
Strategic Partnership Combines Leinco’s Manufacturing Capabilities with IHC and Spatial Biology Validated Antibody Portfolio, plus CellCarta’s CPTAC validated Immuno-MRM Resources to Enhance Clinical ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
You’re on a panel at DPHARM 2024 focused on advancing scalability and operationalizing digital endpoints in clinical trials. What can people expect from this discussion? We’re looking at how we can ...
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer The CHAI platform extracted ...
A multimodal artificial intelligence (MMAI)–derived predictive biomarker was trained for long-term (LT) versus short-term (ST) ADT using pretreatment digital prostate biopsy images and clinical data ...
The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 21-22, 2010, bringing together key stakeholders, to present promising current and emerging technologies with ...
The Global Alzheimer’s Platform Foundation ® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers ...
Digital biomarkers offer major potential, yet the pathway from research to real‑world use remains complex. TNO and Orikami are closing this gap by combining scientific validation with a certified, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results